Study explorer (study characteristics and results) method abbreviations

display ongoing studies
Study studied treatmentcontrol treatmentpatientsrisk of biassample sizes Results

COVID-19 prophylaxis meta-analysis

Abella, 2020
 
NCT04329923
hydroxychloroquineplaceboCOVID-19 prophylaxisNA
65/65 safety concern
  • inconclusive 6 % increase in conversion to SARS-CoV- 2–positive status via NP swab (PE)
  • statistically significant 1.3-fold increase in conversion to SARS-CoV- 2–positive status via NP swab
BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020
 
NCT04304053
RCThydroxychloroquinestandard of careCOVID-19 prophylaxissome concern
1116/1198 safety concern
    no demonstrated benefit a
  • inconclusive 14 % decrease in new illness compatible with Covid-19 ,PCR-confirmed, symptomatic Covid-19 disease (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 19.3-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
COVID PREP (Rajasingham) - HCQ 1x week, 2020
 
NCT04328467
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
494/494 safety concern
  • inconclusive 28 % decrease in new illness compatible with Covid-19 (PE) with a high degree of certainty due to low risk of bias
  • statistically significant 85 % increase in adverse events with a high degree of certainty due to low risk of bias
COVID PREP (Rajasingham) - HCQ 2x week, 2020
 
NCT04328467
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
495/494 safety concern
  • inconclusive 26 % decrease in new illness compatible with Covid-19 (PE) with a high degree of certainty due to low risk of bias
  • statistically significant 1.0-fold increase in adverse events with a high degree of certainty due to low risk of bias
  • statistically significant 1.5-fold increase in adverse events with a high degree of certainty due to low risk of bias
COVID-PEP-Post exposure (Boulware), 2020
 
NCT04308668
RCThydroxychloroquineplaceboCOVID-19 prophylaxislow
414/407 safety concern
    no demonstrated benefit a
  • inconclusive 19 % decrease in new illness compatible with Covid-19 (PE) with a high degree of certainty due to low risk of bias
  • statistically significant 2.3-fold increase in adverse events with a high degree of certainty due to low risk of bias
  • statistically significant 5.8-fold increase in adverse events with a high degree of certainty due to low risk of bias
Grau-Pujol, 2020
 
NCT04331834
RCThydroxychloroquineplaceboCOVID-19 prophylaxissome concern
142/127 inconclusive
    no demonstrated benefit a
PATCH-cohort 3 PreP (Abella), 2020
 
NCT04329923
RCThydroxychloroquineplaceboCOVID-19 prophylaxissome concern
66/66 inconclusive
  • inconclusive 5 % decrease in PCR-confirmed, symptomatic Covid-19 disease,conversion to SARS-CoV- 2–positive status via NP swab (PE) with a moderate degree of certainty due to some concern in risk of bias
Rentsch, 2020OBShydroxychloroquineCOVID-19 prophylaxisNA
-/- ongoing

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);